29 May 2019

PDMR Dealing

RNS Number : 4787A
Verona Pharma PLC
29 May 2019
 

 

Verona Pharma plc

PDMR Dealing

 

May 29, 2019, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, announces that, on May 28, 2019, Kayt  Morgan, spouse of Mr. Piers Morgan, CFO of the Company, purchased 33,802 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 59 pence per Ordinary Share and a total purchase price of £19,954.18Following the acquisition, Mr. Morgan will have a beneficial interest in the Company of 147,009 Ordinary Shares, representing 0.14% of the Company's issued share capital.

This purchase brings the total purchases by Mr. and Mrs. Morgan during the past few months to over £52,000 and follows the purchases made by the Company's Chairman, Dr. David Ebsworth, in March totaling approximately £50,000.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Kayt Morgan

2

Reason for the notification


a)


Position/status

 

Spouse (PCA) of Piers Morgan, Chief Financial Officer

b)

Initial notification/Amendment

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Verona Pharma plc

b)

LEI

 

213800EVI6O6J3TIAL06

 


 

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 5 pence each

GB00BYW2KH80

b)

Nature of the transaction

 

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

59 pence per Ordinary Share

33,802 Ordinary Shares

 

d)

Aggregated information

-         Aggregated volume

-         Price

N/A

 

e)

Date of the transaction

28 May 2019

f)

Place of the transaction

London Stock Exchange, AIM

 

 

 

For further information, please contact:

 

Verona Pharma plc

Tel: +44 (0)20 3283 4200

Jan-Anders Karlsson, Chief Executive Officer

Victoria Stewart, Director of Communications

info@veronapharma.com

N+1 Singer

(Nominated Adviser and UK Broker)

Tel: +44 (0)20 3283 4200

 

Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)

Mia Gardner (Corporate Broking)

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHALMMTMBMTBAL

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Victoria Stewart, Director of Communications
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Brough Ransom /Mia Gardner (Corporate Broking)
Tel: +44 (0)20 3283 4200

 

 

Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Annemarieke Ezendam
Hollie Vile
Tel: +44 (0) 203 922 0891
verona@optimumcomms.com

Westwicke, an ICR Company (Investor enquiries)
Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us